Clinical trials: SARS
Prevention of COVID-19 Caused by SARS-CoV-2
An Investigator Initiated, Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older
Study Objective(s) To evaluate the safety, immunogenicity and protective efficacy of 1 dose of ReCOV in participants who have received 2 or 3 doses of inactivated SARS-CoV-2 vaccination in Chinese adults aged 18 years and older.
- Trial name
- NCT05679466
- Where
- China
- Volunteers
- 3,300 people, healthy volunteers welcome
- Sponsor
- Yu Qin
Hypoxic Pulmonary Vasoconstriction, Hypoxemia
Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction in ARDS Secondary to SARS-CoV2
Summary Currently, the COVID-19 pandemic has overtaken health systems worldwide, exceeding the capacity of intensive care units.
- Conditions
- Hypoxic Pulmonary Vasoconstriction, Hypoxemia, Acute Respiratory Distress Syndrome, SARS-CoV-2 Acute Respiratory Disease
- Trial name
- COVID-19 (NCT04998253)
- Testing
- Effects in oxygenation and hypoxic pulmonary vasoconstriction
- Where
- Mexico
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Unidad Temporal COVID-19 en Centro Citibanamex
COVID-19
Home Usability Study of the SARS-CoV-2 (COVID-19) Test
The primary objective is to determine the usability of the SARS-CoV-2 Specimen Collection Materials for at-home collection and mailing of sample to the testing laboratory.
- Trial name
- NCT04395391
- Testing
- SARS-CoV-2
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
COVID-19 Pneumonia
The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores
This is a study trial to assess the effectiveness of the immune response stimulated by the genetically engineered Bacillus subtilis which express and display Spike protein of the SARS-COV2 on the spore coat.
- Trial name
- NCT05057923
- Testing
- Bacillus subtilis
- Where
- Hong Kong
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- DreamTec Research Limited
Psychosis;Schizophrenic, Personality Disorders
The Impact of the COVID-19 (SARS-CoV-2 Disease) on Psychopathology
The outbreak of the SARS-CoV-2 pandemic may be considered a traumatic phenomenon. In a sample of subjects suffering from different psychiatric disorders, psychopathological status and Post-Traumatic Stress Disorder (PTSD)…
- Conditions
- Psychosis;Schizophrenic, Personality Disorders, Mood Disorders, Anxiety Disorders
- Trial name
- NCT04694482
- Testing
- Psychometric scale administration
- Where
- Italy
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- University of Milano Bicocca
SARS-CoV-2
Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad
This study is a randomized, blinded, parallel-controlled phase 3 clinical trial. The study intent to evaluate the immunogenicity and safety of SARS-CoV-2 mRNA Vaccine (LVRNA009) as heterologous booster in participants aged 18…
- Trial name
- NCT05428592
- Testing
- LVRNA009, CoronaVac®
- Where
- Pakistan
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
COVID-19 Pandemic, COVID-19 Vaccines
INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old
This is an open label, phase III trial - immunobridging study. There will be only 1 group in the study. All subjects (12 to 17 years old) will receive INAVAC 5 µg dose.
- Trial name
- NCT06282692
- Testing
- INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated) 5 µg
- Where
- Indonesia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Dr. Soetomo General Hospital
Safety of a Single Dose of COMVIGEN Vaccine, Reactogenicity of a Single Dose of COMVIGEN Vaccine
Immunogenicity and Safety of Comvigen (Bivalent) Vaccine
This study will assess the safety, reactogenicity and immunogenicity of a single dose of Comvigen (Bivalent, ChulaCov19 BNA159.2) vaccine or BIVALENT Pfizer/BNT vaccine as a booster among healthy males and non-pregnant females…
- Conditions
- Safety of a Single Dose of COMVIGEN Vaccine, Reactogenicity of a Single Dose of COMVIGEN Vaccine, Immunogenicity of a Single Dose of COMVIGEN Vaccine, Safety of a Single Dose of BIVALENT Pfizer/BNT Vaccine
- Trial name
- NCT05930730
- Testing
- Comvigen (Bivalent, ChulaCov19 BNA159.2), BIVALENT Pfizer/BNT vaccine
- Where
- 2 sites in Thailand
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
COVID-19 Stress Syndrome, COVID-19 Vaccine Adverse Reaction
COVID-19 Vaccination Detoxification in LDL-C
The study hypothesizes that SARS-CoV-2 vaccination poisoning hibernates in human host in Low Density Lipoprotein Cholesterol (LDL-C). The clinical trial is a follow-up from the intervention trial with NCT number NCT05711810.
- Conditions
- COVID-19 Stress Syndrome, COVID-19 Vaccine Adverse Reaction, COVID-19-Associated Thromboembolism, COVID-19 Post-Intensive Care Syndrome
- Trial name
- NCT05839236
- Testing
- Atorvastatin Calcium Tablets
- Where
- China
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Yang I. Pachankis
SARS-CoV-2, Covid-19
Immunological Profiling of Patients With COVID-19 in Respiratory Distress
The study investigators hypothesize that the pneumonia arising in patients with COVID-19 is largely of immunopathological origin.
- Trial name
- ACTICOV-2 (NCT04351711)
- Testing
- Immunological profiling
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Cancer
Mechanisms of Anti COVID-19 Humoral and Cellular Immune Response After Vaccination in a Sample of Patients and Salaried Staff From a French Anti-cancer Center
Special populations are people with a risk to dévelop severe forms of a disease. The immunogenicity and efficacy of vaccines in this population may be different compared of the general population.
- Trial name
- CANSEROVAX (NCT04935528)
- Testing
- serology and ELISPOT test, serology
- Where
- France
- Volunteers
- 539 people, healthy volunteers welcome
- Sponsor
- Centre Georges Francois Leclerc
Sars-CoV2
SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak
A novel zoonotic coronavirus was discovered in Wuhan (Hubei Province, China) mid-December 2019 and was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- COVEMUZ (NCT04426292)
- Testing
- Serological testing
- Where
- Belgium
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Covid19, Angiogenesis
Endothelial Damage and Angiogenesis Biomarkers During COVID-19
Severe SARS-CoV-2 disease is characterized by a progressive hypoxemic respiratory failure. Autopsies from these patients show severe endothelial damage with extensive vascular thrombosis, microangiopathy, and occlusion of…
- Conditions
- Covid19, Angiogenesis, Endothelial Dysfunction, Cardiovascular Morbidity
- Trial name
- NCT04609332
- Testing
- Endothelial damage and angiogenic biomarkers
- Where
- Chile
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Chile
COVID19, Sars-Cov-2
The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus
COV2 is a nasal, investigational vaccine against COVID-19, based on a serotype 5 adenoviral vector producing the SARS-CoV-2 spike protein.
- Trial name
- COV2NOSE (NCT06851611)
- Testing
- COVID-19 vaccine, low dose level, COVID-19 vaccine, high dose level, Nasal Drops
- Where
- Finland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Rokote Laboratories Finland Oy
Influenza, Human, SARS-CoV-2 Infection
Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection
The objectives of this study are to understand the long-term consequences of repeated annual influenza vaccination among healthcare workers (HCWs) and to use statistical and mathematical modelling to elucidate the immunological…
- Trial name
- NCT05110911
- Testing
- Influenza vaccination: Fluarix Tetra, Vaxigrip Tetra, Fluquadri, Fluad Quad, Afluia Quad, Flucelvax Quad, SARS-CoV-2 vaccination: Comirnaty or Vaxzevria
- Where
- 6 sites in Australia
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University of Melbourne
COVID-19, SARS-CoV-2 Infection, RSV
Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)
The purpose of this study is to comprehensively describe the temporal and geographic utilization of COVID-19 therapies used for mild to moderate disease during different periods of SARS-CoV-2 variant circulation as well as to…
- Conditions
- COVID-19, SARS-CoV-2 Infection, RSV, Influenza
- Trial name
- COPE-VA (NCT06160128)
- Where
- United States
- Volunteers
- 400,000 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
COVID-19
Clinical Outcomes of paTients pREsenting to HArare COVID-19 CenTer of Excellence With SARS-CoV-2 Infection
In order to influence COVID-19 treatment guidelines, evidence on disease progression and clinical outcomes of hospitalized COVID-19 patients, particularly those receiving innovative COVID-19 medications in an African setting is…
- Trial name
- TREAT (NCT05529771)
- Where
- Zimbabwe
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- Elizabeth Glaser Pediatric AIDS Foundation
SARS-CoV Infection, Covid19
COVID-19: SARS-CoV-2 Detection in Saliva, Oropharyngeal and Nasopharyngeal Specimens
The aim of this study is to compare the SARS-CoV-2 detection rate using either a Saliva, oropharyngeal swabs or nasopharyngeal swab method for specimen collection.
- Conditions
- SARS-CoV Infection, Covid19, Coronavirus
- Trial name
- NCT04715607
- Testing
- Sequence of testing.
- Where
- Denmark
- Volunteers
- 27,947 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Covid19
The Salivary Raman COVID-19 Fingerprint
The outbreak of coronavirus disease 2019 (COVID-19), caused by infection of SARS-CoV-2, has rapidly spread to become a worldwide pandemic.
- Trial name
- NCT04583306
- Testing
- Raman analysis of saliva, characterization of the Raman database and building of the classification model
- Where
- 5 sites in Italy
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Fondazione Don Carlo Gnocchi ETS
COVID-19, SARS-CoV-2 Infection
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine
The objective of study is to evaluate the immunogenicity and safety of SCTV01C or SCTV01E as booster compared with Sinopharm inactivated COVID-19 vaccine as booster.
- Trial name
- NCT05239806
- Testing
- SCTV01C, SCTV01E, Sinopharm inactivated COVID-19 vaccine
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.